Results from the RESPIRE trials fell short of expectations but even so offer hope for bronchiectasis, providing important lessons for future clinical trials and disease management, experts say. The RESPIRE trials – together the largest clinical trial program ever conducted in bronchiectasis – evaluated 32.5 mg ciprofloxacin dry powder inhalation twice-daily as a treatment for ...
Valuable lessons learned from failed bronchiectasis trial
By Jennie James
22 Feb 2018